Abstract:Background: Microglial activation-mediated neuroinflammation plays an important role in the progression of neurodegenerative diseases. Inflammatory activation of microglial cells is often accompanied by a metabolic switch from oxidative phosphorylation to aerobic glycolysis. However, the roles and molecular mechanisms of glycolysis in microglial activation and neuroinflammation are not yet fully understood. Methods: The anti-inflammatory effects and its underlying mechanisms of glycolytic inhibition in vitro were examined in lipopolysaccharide (LPS) activated BV-2 microglial cells or primary microglial cells by enzyme-linked immunosorbent assay (ELISA), quantitative reverse transcriptase-polymerase chain reaction (RT-PCR), Western blot, immunoprecipitation, flow cytometry, and nuclear factor kappa B (NF-κB) luciferase reporter assays. The anti-inflammatory and neuroprotective effects of glycolytic inhibitor, 2-deoxoy-D-glucose (2-DG) in vivo were measured in the 1-methyl-4-phenyl-1,2,3,6-tetrahydropyridine (MPTP)-or LPS-induced Parkinson's disease (PD) models by immunofluorescence staining, behavior tests, and Western blot analysis. Results: We found that LPS rapidly increased glycolysis in microglial cells, and glycolysis inhibitors (2-DG and 3-bromopyruvic acid (3-BPA)), siRNA glucose transporter type 1 (Glut-1), and siRNA hexokinase (HK) 2 abolished LPS-induced microglial cell activation. Mechanistic studies demonstrated that glycolysis inhibitors significantly inhibited LPS-induced phosphorylation of mechanistic target of rapamycin (mTOR), an inhibitor of nuclear factor-kappa B kinase subunit beta (IKKβ), and NF-kappa-B inhibitor alpha (IκB-α), degradation of IκBα, nuclear translocation of p65 subunit of NF-κB, and NF-κB transcriptional activity. In addition, 2-DG significantly inhibited LPS-induced acetylation of p65/RelA on lysine 310, which is mediated by NAD-dependent protein deacetylase sirtuin-1 (SIRT1) and is critical for NF-κB activation. A coculture study revealed that 2-DG reduced the cytotoxicity of activated microglia toward MES23.5 dopaminergic neuron cells with no direct protective effect. In an LPS-induced PD model, 2-DG significantly ameliorated neuroinflammation and subsequent tyrosine hydroxylase (TH)-positive cell loss. Furthermore, 2-DG also reduced dopaminergic cell death and microglial activation in the MPTP-induced PD model. Conclusions: Collectively, our results suggest that glycolysis is actively involved in microglial activation. Inhibition of glycolysis can ameliorate microglial activation-related neuroinflammatory diseases.

Low-Level Laser Therapy Regulates Microglial Function Through Src-Mediated Signaling Pathways: Implications for Neurodegenerative Diseases

Low-power laser irradiation (LPLI) attenuates microglial cytotoxicity through the activation of Src pathway

Effects of LPLI on Microglial Phagocytosis in LPS-induced Neuroinflammation Model

Low-level laser facilitates alternatively activated macrophage/microglia polarization and promotes functional recovery after crush spinal cord injury in rats

Low‐level laser therapy 810‐nm up‐regulates macrophage secretion of neurotrophic factors via PKA‐CREB and promotes neuronal axon regeneration in vitro

Low-level laser therapy rescues dendrite atrophy via upregulating BDNF expression: implications for Alzheimer's disease.

The Effect of Low Level Laser Therapy on Macrophage Polarization after Acute Spinal Cord Injury In Rats

Low-level Laser Therapy Promotes Dendrite Growth Via Upregulating Brain-Derived Neurotrophic Factor Expression

Microglia mediated neuroinflammation - signaling regulation and therapeutic considerations with special reference to some natural compounds

Combined Effects of Low Level Laser Therapy and Inducers on the Neural Differentiation of Mesenchymal Stem Cells

Activation of the MAC1-ERK1/2-NOX2 Pathway Is Required for LPS-Induced Sustaining Reactive Microgliosis, Chronic Neuroinflammation and Neurodegeneration

Early glycolytic reprogramming controls microglial inflammatory activation

Src Inhibition Attenuates Neuroinflammation and Protects Dopaminergic Neurons in Parkinson's Disease Models

LRP1 Modulates the Microglial Immune Response Via Regulation of JNK and NF-κB Signaling Pathways

Luteolin Inhibits SH-SY5Y Cell Apoptosis Through Suppression of the Nuclear Transcription Factor-Κb, Mitogen-Activated Protein Kinase and Protein Kinase B Pathways in Lipopolysaccharide-Stimulated Cocultured BV2 Cells.

Activation of the MAC1-ERK1/2-NOX2 Pathway is Required for LPS-Induced Sustaining Reactive Microgliosis, Chronic Neuroinflammation and Neurodegeneration.

Luteolin Mitigates Dopaminergic Neuron Degeneration and Restrains Microglial M1 Polarization by Inhibiting Toll Like Receptor 4

Reactive Microgliosis Participates in MPP+‐induced Dopaminergic Neurodegeneration: Role of 67 Kda Laminin Receptor

The role of ZC3H12D-regulated TLR4-NF-κB pathway in LPS-induced pro-inflammatory microglial activation

Low-level laser therapy for beta amyloid toxicity in rat hippocampus

LRP1 knockdown aggravates A<sub>1-42</sub>-stimulated microglial and astrocytic neuroinflammatory responses by modulating TLR4/NF-B/MAPKs signaling pathways